All In Biotech

Drug Trial Radar · NCT05835310

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of IV Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Moderate to Severe Active Systemic Lupus Erythematosus While on Background Standard of Care Therapy

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Mar 14, 2024

Primary completion

Oct 5, 2028

Study completion Jan 9, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • AnifrolumabBiological

    Participants will receive anifrolumab via IV infusion.

  • PlaceboDrug

    Participants will receive matching placebo via IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A- Anifrolumab serum concentrationTime frame: Pre-dose Day 29
  2. Part A - Maximum observed serum (peak) drug concentration (Cmax)Time frame: Up to Day 29
  3. Part A - Area under the serum concentration curve (AUC)Time frame: Up to Day 29
  4. Part A - Minimum observed serum concentration (Cmin)Time frame: Up to Day 29
  5. Part B - Number of participants who are British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) responders (yes/no)Time frame: At Week 52

Locations

111 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    Washington D.C., District of Columbia · Recruiting

  • Research Site

    St. Petersburg, Florida · Not yet recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    New Orleans, Louisiana · Recruiting

  • Research Site

    Bethesda, Maryland · Withdrawn

  • Research Site

    Saint Paul, Minnesota · Recruiting

  • Research Site

    New Hyde Park, New York · Recruiting

  • Research Site

    New York, New York · Recruiting

  • Research Site

    The Bronx, New York · Recruiting

  • Research Site

    Valhalla, New York · Recruiting

  • Research Site

    Durham, North Carolina · Recruiting

  • Research Site

    Cincinnati, Ohio · Recruiting

  • Research Site

    Cleveland, Ohio · Recruiting

  • Research Site

    Columbus, Ohio · Recruiting

  • Research Site

    Portland, Oregon · Recruiting

  • Research Site

    Philadelphia, Pennsylvania · Recruiting

  • Research Site

    Greenville, South Carolina · Withdrawn

  • Research Site

    El Paso, Texas · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Salt Lake City, Utah · Recruiting

  • Research Site

    Buenos Aires, Argentina · Withdrawn

  • Research Site

    Córdoba, Argentina · Recruiting

  • Research Site

    Rosario, Argentina · Recruiting

  • Research Site

    San Miguel de Tucumán, Argentina · Recruiting

  • Research Site

    Belo Horizonte, Brazil · Not yet recruiting

  • Research Site

    Belo Horizonte, Brazil · Not yet recruiting

  • Research Site

    Belo Horizonte, Brazil · Not yet recruiting

  • Research Site

    Porto Alegre, Brazil · Recruiting

  • Research Site

    Ribeirão Preto, Brazil · Recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    São Paulo, Brazil · Recruiting

  • Research Site

    Calgary, Alberta, Canada · Not yet recruiting

  • Research Site

    Vancouver, British Columbia, Canada · Recruiting

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Beijing, China · Withdrawn

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.